valopicitabine

Valopicitabine is an orally administered small molecule antiviral drug developed as a prodrug of the nucleoside analog 2'-C-methylcytidine, primarily for the treatment of hepatitis C virus (HCV) infection. After administration, it is converted in the body to its active form, 2'-C-methylcytidine triphosphate. This metabolite inhibits HCV RNA-dependent RNA polymerase (NS5B), blocking viral RNA chain elongation and thus halting viral replication. Valopicitabine demonstrated pan-genotypic activity against HCV and was investigated in combination with pegylated interferon for patients with chronic hepatitis C genotype 1, including those who had failed previous treatments. The drug reached up to Phase III clinical trials but was not approved for marketing[1][3][5][6][7][8].

Other names

Valopicitabine dihydrochloridevalopicitabina